Home / Peptides / Elamipretide
Elamipretide (SS-31) Dosage Chart and Schedule
FDA-approved (rare disease)
Mitochondria-targeted peptide (Forzinity), approved 2025 only for Barth syndrome. Label: 40 mg daily.
Also called: SS-31, Forzinity, MTP-131, Bendavia
Regulatory status (US)
FDA accelerated approval on September 19, 2025 as Forzinity, to improve muscle strength in people with Barth syndrome who weigh at least 30 kg. A confirmatory trial is required. It has no approved use outside Barth syndrome.
What it is
A small four-amino-acid peptide that binds cardiolipin in the inner membrane of mitochondria.
Label dose (Forzinity)
| Patients | Dose | Product |
|---|---|---|
| Barth syndrome, 30 kg or more | 40 mg under the skin once daily | 280 mg / 3.5 mL vial (80 mg/mL) |
From the Forzinity label. Supplied as a ready-to-use solution; discard 8 days after first opening.
Elamipretide reconstitution calculator
Enter your vial and your prescribed dose to see the units on a U-100 syringe.
What human studies show
- Approval was based on knee-extensor muscle strength in Barth syndrome (TAZPOWER).
Safety
- Injection-site reactions were the most common side effect.
- Contains benzyl alcohol; not approved in newborns.
Questions
- Is Elamipretide FDA-approved?
- FDA accelerated approval on September 19, 2025 as Forzinity, to improve muscle strength in people with Barth syndrome who weigh at least 30 kg. A confirmatory trial is required. It has no approved use outside Barth syndrome.
- What dose of Elamipretide has been studied?
- Barth syndrome, 30 kg or more: 40 mg under the skin once daily: 280 mg / 3.5 mL vial (80 mg/mL). From the Forzinity label. Supplied as a ready-to-use solution; discard 8 days after first opening.
- How many units is my Elamipretide dose?
- Divide the mg in the vial by the mL of bacteriostatic water to get mg/mL, divide your dose in mg by that, and multiply by 100 for units on a U-100 syringe. The calculator on this page does it and draws the syringe.
Related
Weekly GIP and GLP-1 agonist (Mounjaro, Zepbound). Label: 2.5 mg start, +2.5 mg every 4 weeks, max 15 mg.
SemaglutideWeekly GLP-1 agonist (Ozempic, Wegovy). Wegovy label: 0.25 mg start, up to 2.4 mg, or 7.2 mg (HD).
Orforglipron (Foundayo)Daily GLP-1 pill from Lilly (Foundayo), approved April 2026. Not a peptide and never reconstituted.
TesamorelinGHRH analogue (Egrifta) approved for HIV-associated abdominal fat. Egrifta WR: 1.28 mg daily.
Sources
- DailyMed: Forzinity (elamipretide) labeling
- Stealth BioTherapeutics: FDA accelerated approval of Forzinity (Sep 2025)
- FDA 510(k) K212499: BD insulin syringes for U-100 insulin
Last checked 2026-11-16. How we pick and check sources: methodology.